Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IGILUC 2019 /
Multi-target kinase inhibitors: From data to practice

18th - 19th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.05.19
Views: 737
Rating:

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Prof Heinz-Josef Lenz speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the use of multi-target kinase inhibitors in the third-line setting and beyond.

Prof Lenz describes the use of regorafenib which detects angiogenesis, tumour growth, metastatic potential and immune response pathways.

He also discusses the effects of regorafenib on progression-free and overall survival and the recommended dose in order to achieve efficacy.

Prof Lenz also states the difficulty in identifying successful combinations to convert an immunologically cold tumour into a hot one in patients with colorectal cancer.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation